Would you consider using bevacizumab/atezolizumab in HCC patients who received TKI in the first line?   

This is a great question. After failure of a front-line single agent TKI, I would still favor the current FDA-approved agents: regorafenib; cabozantinib; ramucirumab in AFP-high; OR immunotherapy (nivolumab, pembrolizumab, OR nivolumab plus ipilimumab).  It is important to note that the second...

This is absolutely appropriate. The combination is highly active and should work after a multi TKI. But the data exist only for CP-A and those who had esophageal varices controlled with a recent endoscopy. Be aware of the potential for (fatal) GI bleeding. A study in B7 (The AB7) study will be condu...